Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,627.07
    -1,861.33 (-3.69%)
     

  • CMC Crypto 200

    1,258.70
    -99.31 (-7.31%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Sarepta says FDA raises doubt about drug trial, shares drop 39 pct

Reuters - UK Focus

Nov 12 (Reuters) - Sarepta Therapeutics Inc (NasdaqGM: SRPT - news) said the U.S. Food and Drug Administration had raised concerns about the trial for the company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature.

Sarepta shares fell 39 percent to $22.20 in premarket trade on Tuesday.

The FDA said the recent trial failure of a competing drug made by GlaxoSmithKline (Other OTC: GLAXF - news) and Prosensa had raised "considerable doubt" about Sarepta's trial. (Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)